Revised edition after only eight years

Under the direction of the BREATH scientist Prof. Dr. Burkhard Tümmler, the second edition of the monograph „Mutation-specific therapies in cystic fibrosis“ has now been published.

Prof. Dr. Burkhard Tümmler, a scientist at BREATH (Biomedical Research in Endstage and Obstructive Lung Disease), the Hanover site of the German Center for Lung Research (DZL), has dedicated himself to cystic fibrosis (CF), also known as mucoviscidosis. He has conducted and promoted research in this field already for decades together with his working group and is considered to be an international expert. The progress of his successful work for the diagnosis and treatment of cystic fibrosis can be seen recently in the updated edition of the monograph „Mutation-specific therapies in cystic fibrosis“.


In 2014, the first edition was published under Tümmler‘s direction, in which the focus was on the fundamental principles of the disease and the then current  state of research. Just eight years later, the second edition of the monograph has been published. „In the past few years we have collected so many new findings for the therapy of cystic fibrosis that we have completely revised about 70% of the content and totally reworked the rest“, says the researcher. He is clearly proud of his team at the Hanover site and the worldwide established network. „With the help of the DZL, we have been able to raise our research to the highest level. As a result, our expertise is internationally sought after and we have once again been able to count on worldwide acclaimed researchers for the second edtion of the monograph.“ 


Readers will be given an insight into the basic research and clinical use of cystic fibrosis transmembrane conductance regulator (CFTR) modulators. From the laboratory bench to the hospital bed – this demand on the CF research forms a large part of the second edition. Working together with researchers from the pediatric, radiology and pathology departments withIn the DZL, knowledge about CFTR modulators could be validated by the research carried out in clinical studies. 
„There are still so many open questions in the CF research, on which we will continue to work with total commitment“, says Tümmler, who contributes with his work to the broader clarification of the function and therapy of cystic fibrosis. 
 

Text: BREATH/AB

Photo: MHH/Figil

 

Publication:

Tümmler B (Hrsg) Mutation-specific therapies in cystic fibrosis., 2nd Edition 2022, UNI-MED Science, Bremen, 128 pp

ISBN 978-3-8374-1630-5 und ISBN 987-3-8374-5630-1

Prof. Dr. Burkhard Tümmler